Warning OncoMed Pharmaceuticals, Inc. (OMED) optimists! Robert Stagg just Sold 4,051 shares.; Covington Capital Management Has Increased By $321,296 Its Mcdonalds (MCD) Stake

McDonald's Corporation (NYSE:MCD) Logo

Covington Capital Management increased Mcdonalds Corp (MCD) stake by 4.29% reported in 2017Q4 SEC filing. Covington Capital Management acquired 1,868 shares as Mcdonalds Corp (MCD)’s stock declined 8.13%. The Covington Capital Management holds 45,404 shares with $7.82 million value, up from 43,536 last quarter. Mcdonalds Corp now has $124.91B valuation. The stock increased 1.90% or $2.96 during the last trading session, reaching $158.9. About 3.68M shares traded. McDonald's Corporation (NYSE:MCD) has risen 21.62% since April 27, 2017 and is uptrending. It has outperformed by 10.07% the S&P500.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on May, 14. They expect $-0.24 earnings per share, up 60.66% or $0.37 from last year’s $-0.61 per share. After $0.25 actual earnings per share reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -196.00% negative EPS growth.

Investors sentiment increased to 1.62 in Q4 2017. Its up 0.91, from 0.71 in 2017Q3. It increased, as 3 investors sold OncoMed Pharmaceuticals, Inc. shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 19.21 million shares or 47.57% more from 13.02 million shares in 2017Q3 were reported. Nj State Employees Deferred Compensation Plan invested 0.03% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Goldman Sachs Group Inc Incorporated Inc owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 52,106 shares. Jacobs Levy Equity Inc has 48,400 shares. Drw Secs stated it has 13,740 shares or 0.01% of all its holdings. Renaissance Techs Ltd Com owns 529,300 shares. Vanguard Group Inc has 998,147 shares. Tudor Inv Corporation Et Al invested in 0% or 40,795 shares. Millennium Mngmt Limited Liability Corporation holds 543,335 shares. Zacks Inv Mngmt invested in 0% or 21,597 shares. Axa holds 131,785 shares. Bluecrest holds 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 32,382 shares. Cannell Peter B & Co owns 303,971 shares or 0.04% of their US portfolio. D E Shaw Inc reported 280,930 shares. Pdt Ptnrs Ltd Limited Liability Company accumulated 0.01% or 59,100 shares. 28,707 were reported by Bank & Trust Of Ny Mellon Corporation.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $115.54 million. The company??s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

SVP – Clinical R&D, Robert Stagg is the Oncomed Pharmaceuticals Inc’s insider who made a sale of shares of Oncomed Pharmaceuticals Inc, 4,051 to be precise. The sold shares were based on an average stock price of $2.7, with Robert Stagg’s sale valued at $10,848 U.S. Dollars. Right now, Robert Stagg owns 43,283 shares which are equivalent to roughly 0.11% of the Company’s market cap (share price times the number of shares outstanding).

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. OncoMed Pharmaceuticals has $40 highest and $3.0 lowest target. $7.63’s average target is 152.65% above currents $3.02 stock price. OncoMed Pharmaceuticals had 21 analyst reports since September 9, 2015 according to SRatingsIntel. The company was initiated on Friday, December 4 by Wells Fargo. The company was maintained on Thursday, March 8 by SunTrust. H.C. Wainwright initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Thursday, September 22 with “Buy” rating. As per Thursday, August 24, the company rating was maintained by Jefferies. The stock has “Buy” rating by SunTrust on Tuesday, December 20. BMO Capital Markets initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Tuesday, April 12 with “Outperform” rating. The firm earned “Hold” rating on Friday, October 6 by SunTrust. Jefferies initiated it with “Buy” rating and $32 target in Wednesday, September 9 report. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) earned “Hold” rating by H.C. Wainwright on Friday, March 9. The firm has “Buy” rating by Jefferies given on Tuesday, September 26.

The stock increased 3.60% or $0.11 during the last trading session, reaching $3.02. About 130,268 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 65.75% since April 27, 2017 and is downtrending. It has underperformed by 77.30% the S&P500.

Among 35 analysts covering McDonald’s Corporation (NYSE:MCD), 24 have Buy rating, 1 Sell and 10 Hold. Therefore 69% are positive. McDonald’s Corporation had 149 analyst reports since September 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, April 17 by SunTrust. The firm has “Hold” rating by Canaccord Genuity given on Friday, January 5. Barclays Capital maintained McDonald's Corporation (NYSE:MCD) on Wednesday, November 11 with “Overweight” rating. On Wednesday, July 19 the stock rating was maintained by Jefferies with “Hold”. Robert W. Baird maintained the shares of MCD in report on Monday, October 2 with “Buy” rating. The firm has “Buy” rating by Mizuho given on Tuesday, January 30. The company was maintained on Thursday, October 5 by Canaccord Genuity. The firm earned “Equal-Weight” rating on Monday, March 26 by Morgan Stanley. UBS downgraded the shares of MCD in report on Friday, January 6 to “Neutral” rating. The stock of McDonald's Corporation (NYSE:MCD) has “Hold” rating given on Wednesday, January 3 by Stifel Nicolaus.

Covington Capital Management decreased Allergan Plc stake by 25,227 shares to 19,757 valued at $3.23M in 2017Q4. It also reduced Stericycle Inc (NASDAQ:SRCL) stake by 12,865 shares and now owns 50,695 shares. Avery Dennison Corp (NYSE:AVY) was reduced too.

McDonald's Corporation (NYSE:MCD) Institutional Positions Chart